Recent developments include the launch of LYMPHIR, distribution agreements with major healthcare distributors, capital raises, and reported financial losses.

• Citius Oncology launched LYMPHIR, the first CTCL systemic therapy in over seven years, in December 2025 [N3].
• The company inked distribution services agreements with McKesson and Cardinal Health for LYMPHIR in 2025 [N4][N8].
• Citius Oncology raised $9 million through a direct offering and private placement in September 2025 [N5].
• The company reported increased full-year losses in 2025 [N2].
• In Q2 FY 2026, Citius reported a $21 million loss and shares declined by over 20% [N1].
• The company beat fiscal Q3 EPS in 2025 [N6].

Citius Oncology has achieved FDA approval and commercial launch of LYMPHIR, the first systemic therapy for CTCL in over seven years, addressing an underserved market estimated to exceed $400 million. The company has established key distribution partnerships with McKesson and Cardinal Health, supporting product availability. Clinical trial data demonstrate a meaningful objective response rate and manageable safety profile, which may support adoption by oncology centers. Recent capital raises provide additional funding to support operations. The company's strategy to commercialize independently in the U.S. and partner internationally could enable revenue diversification.

The company reported significant net losses and a current ratio below 1.0 as of June 30, 2026, indicating liquidity constraints. Substantial indebtedness with a high-interest rate floor and balloon payment creates financial risk, including potential asset foreclosure and dilution from loan principal conversion and warrant exercises. Additional funding tranches are contingent on achieving revenue and liquidity milestones, which if unmet, could impair operations. The niche market for LYMPHIR and competition from other oncology therapies may limit commercial success. Adverse events associated with LYMPHIR and the need for ongoing monitoring may affect market acceptance.

Citius Oncology's moat is primarily based on its FDA-approved lead product LYMPHIR, which is an improved formulation of a previously approved oncology agent with a differentiated mechanism of action targeting IL-2 receptors on tumor cells and regulatory T lymphocytes. The company benefits from regulatory exclusivity and intellectual property rights acquired through licensing agreements. Its focused commercialization strategy with a targeted oncology sales force and distribution agreements with major healthcare distributors supports market penetration in a niche, underserved indication. However, the company's competitive position depends on successful commercialization, ongoing clinical validation, and managing financial and operational risks associated with its indebtedness and market dynamics.

• Financial and Liquidity Risks: The company has substantial indebtedness under a loan agreement with a floating interest rate floor of 12.75% and a balloon payment at maturity. Failure to meet debt service obligations or achieve revenue and liquidity milestones could impair operations and lead to asset foreclosure.
• Dilution Risk: Conversion of loan principal and exercise of lender warrants could result in significant dilution to existing stockholders, potentially depressing the market price of common stock.
• Commercialization Risk: The success of LYMPHIR depends on effective commercialization efforts, market acceptance in a niche indication, and competition from other therapies.
• Clinical and Safety Risks: Although LYMPHIR demonstrated tolerability in trials, serious adverse reactions occurred in 38% of patients, which may impact patient acceptance and regulatory scrutiny.

• Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies, headquartered in Cranford, New Jersey [S1].
• The company's lead product is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for treating persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma [S1].
• LYMPHIR was approved by the FDA in August 2024 and launched in December 2025 [S1].
• The company estimates the market for LYMPHIR to exceed $400 million and considers it underserved by existing treatments [S1].
• Citius Oncology intends to commercialize products independently in the U.S. and partner for marketing outside the U.S. It has established a small targeted oncology sales force focused on major cancer centers [S1].
• LYMPHIR is an improved formulation of the oncology agent ONTAK, previously FDA approved, with a pivotal Phase 3 trial (E7777-G000-302) completed in December 2021 demonstrating tolerability and clinical benefit [S1].
• The Phase 3 trial showed an objective response rate (ORR) of 36.2% with 8.7% complete response and 27.5% partial response in patients with relapsed or refractory Stage I-III CTCL [S1].
• Median duration of response was 6.5 months and median time to response was 1.4 months [S1].
• LYMPHIR was generally well tolerated with mostly low grade 1 or 2 adverse events; serious adverse reactions occurred in 38% of patients, including capillary leak syndrome, infusion-related reactions, and sepsis [S1].
• The company has entered distribution agreements for LYMPHIR with McKesson and Cardinal Health [N4][N8].
• Citius Oncology raised $9 million through a direct offering and private placement in September 2025 [N5].
• The company reported a $21 million loss in Q2 FY 2026 and a full year loss increase in 2025 [N1][N2].
• Financial snapshot as of June 30, 2026, shows cash and equivalents of $16.6 million, current assets of $42.7 million, current liabilities of $58.8 million, resulting in a current ratio of 0.73 and cash ratio of 0.28 [S2].
• Revenue for the quarter ending June 30, 2026, was approximately $1.5 million with a net loss of $8.9 million and basic and diluted EPS of -$0.08 [S2].
• The company has substantial indebtedness under a loan agreement with a floating interest rate floor of 12.75% per annum and a balloon payment of $1,062,500 at maturity, secured by a lien on substantially all assets including intellectual property [S2].
• Additional funding tranches under the loan agreement are contingent on achieving specified net revenue and liquidity milestones, with failure to meet these milestones potentially impairing operations and liquidity [S2].
• Conversion of loan principal and exercise of lender warrants could result in significant dilution to existing stockholders [S2].